Gossamer Bio, Inc.

Gossamer Bio, Inc. (GOSS) priced its initial public offering on Feb 8, 2019 at $16.00 per share, raising $276M, and listed on Nasdaq Global Select. At the IPO price its market capitalization was about $1.01B. Leerink Partners was lead-left underwriter, joined by Barclays and Evercore ISI. Latham & Watkins advised the company and Cooley advised the underwriters.

Gossamer Bio, Inc. is a clinical-stage biopharmaceutical company that discovers, acquires, develops and commercializes therapeutics for immunology, inflammation and oncology. It pursues product candidates for indications with high unmet medical need.

Status

IPO

Ticker

GOSS

Exchange

Nasdaq Global Select

Priced

Feb 8, 2019

IPO price

$16.00

Raised

$276M

Market cap at IPO price

$1.01B

First filed

Dec 21, 2018

Underwriters

Leerink Partners, Barclays and Evercore ISI

Company counsel

Latham & Watkins

Underwriters' counsel

Cooley

Sector

Biotech & pharma

Country / state

CA

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.